Merck KGaA, Darmstadt, Germany, has completed its acquisition of SpringWorks Therapeutics, a Stamford, Connecticut-based commercial-stage bio/pharmaceutical company focused on severe rare diseases and cancer, for $3.4 billion. The deal was announced in April 2025. 

SpringWorks’ commercial products include Ogsiveo (nirogacestat) for treating adult patients with progressing desmoid tumors, a rare subtype of soft-tissue sarcomas. The drug is approved in the US, and in June 2025, the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of nirogacestat. 

The company also received approval earlier this year (February 2025) from the US Food and Drug Administration (FDA) for Gomekli (mirdametinib) for treating adult and pediatric patients 2 years of age and older with neurofibromatosis Type 1, a genetic condition that causes changes in skin pigment and tumors on nerve tissue. The marketing authorization application for mirdametinib has been validated by EMA with a potential approval in 2025. SpringWorks additionally has a pipeline of drugs focused on oncology and rare diseases. 

Source: Merck KGaA